Welcome to our dedicated page for Vertex Pharmaceuticals SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vertex Pharmaceuticals filings document the biotechnology company’s operating results, governance and product-development disclosures. Recent Form 8-K reports include quarterly and annual results releases, selected regulatory and pipeline events involving therapies such as povetacicept, and officer or director transition disclosures.
The company’s proxy materials cover board composition, director nominees, shareholder meeting matters, executive compensation and equity-award information. Vertex filings also provide formal records for disclosure topics tied to its approved medicines, clinical pipeline and governance structure as a Nasdaq-listed operating company.
Vertex Pharmaceuticals disclosed that director Suketu Upadhyay has decided not to stand for re-election at the company’s 2026 annual meeting of shareholders. He was recently named the forthcoming Chief Financial Officer of Incyte Corporation and cited scheduling conflicts with this new role.
Upadhyay will continue serving on the board until the 2026 annual meeting. The company stated that his decision did not involve any disagreement regarding its operations, policies, or practices. Following his departure, the board intends to reduce its size to ten members and the existing proxy materials are deemed amended to remove him from the slate of nominees, while all other nominees and previously submitted votes remain in effect.
Upadhyay Suketu reported acquisition or exercise transactions in this Form 4 filing.
Vertex Pharmaceuticals director Suketu Upadhyay received a grant of 80.508 deferred stock units on common stock, recorded at a reference price of $442.50 per unit. Following this award, he holds a total of 2,799.156 deferred stock units.
Each deferred stock unit represents one share of common stock and will be paid in stock upon the earliest of his termination from the board, a company change of control, or his disability or death. This is a compensation-related award rather than an open-market trade.
SACHS BRUCE I reported acquisition or exercise transactions in this Form 4 filing.
Vertex Pharmaceuticals director Bruce I. Sachs received a routine equity grant in the form of deferred stock units. He was awarded 107.345 deferred stock units at a reference price of $442.50 per unit, each representing one share of common stock. After this grant, Sachs holds 15,671.866 deferred stock units. According to the terms, these units are paid out in common stock upon the earliest of his board service ending, a change of control of the company, or his disability or death.
Garber Alan M reported acquisition or exercise transactions in this Form 4 filing.
Vertex Pharmaceuticals director Alan M. Garber received a grant of 33.898 deferred stock units, each tied to one share of common stock. The units were valued at $442.50 per share and are payable in common stock upon the earliest of his board service ending, a change of control, or his disability or death. This represents routine equity-based board compensation rather than an open-market stock purchase or sale.
Vertex Pharmaceuticals executive Joy Liu, EVP and Chief Legal Officer, sold 978 shares of Common Stock in an open-market transaction on April 1, 2026, at an average price of $449.17 per share. The sale was made under a company-approved Rule 10b5-1 trading plan entered into on November 25, 2025.
Following this planned sale, Liu directly holds 21,833 Vertex shares. The filing characterizes this as a routine insider transaction executed pursuant to a pre-arranged trading plan rather than a discretionary trade based on short-term market views.
Vertex Pharmaceuticals asks shareholders to elect eleven directors, ratify its auditor, approve 2025 executive pay on an advisory basis, adopt a 2026 Stock and Option Plan, and vote on a shareholder written-consent proposal. The meeting will be held virtually on May 13, 2026.
Management highlights 2025 total revenues of $12 billion, 9% growth versus 2024, driven by cystic fibrosis medicines, CASGEVY and the first year of JOURNAVX sales, and reports $12.3 billion in cash and investments at year-end. The proxy emphasizes a broad late-stage pipeline, strong say‑on‑pay support of about 92% in 2025, and a pay‑for‑performance program with a high mix of performance stock units for senior executives.
Vertex Pharmaceuticals (VRTX) Rule 144 notice reporting planned resale of 978 shares of common stock related to a Restricted Stock Vesting event dated 02/17/2025. The filing also lists recent sales by Joy Liu: 1,385 shares on 01/05/2026 for $621,629.55, 812 shares on 02/12/2026 for $375,282.04, 9,320 shares on 02/13/2026 for $4,557,480.00, and 892 shares on 03/02/2026 for $442,396.32.
Vertex Pharmaceuticals executive Carmen Bozic reported an open-market sale of company stock. On March 27, 2026, she sold 2,329 shares of Common Stock at an average price of $450.95 per share. After this transaction, she directly holds 33,076 shares. The sale was made under a pre-arranged Rule 10b5-1 trading plan that Dr. Bozic entered into on November 20, 2025, indicating the timing was set in advance.
Vertex Pharmaceuticals has completed submission of a rolling Biologics License Application to the FDA for povetacicept, seeking potential accelerated approval to treat immunoglobulin A nephropathy in adults. Vertex used a priority review voucher and therefore expects the FDA’s review to be expedited to six months from acceptance versus the typical ten-month review.